amylase

(redirected from hyperamylasemia)
Also found in: Thesaurus, Medical, Encyclopedia.

am·y·lase

 (ăm′ə-lās′, -lāz′)
n.
Any of a group of enzymes that catalyze the hydrolysis of starch to sugars. In humans, amylases are produced in the salivary glands and the pancreas.

amylase

(ˈæmɪˌleɪz)
n
(Biochemistry) any of several enzymes that hydrolyse starch and glycogen to simple sugars, such as glucose. They are present in saliva

am•yl•ase

(ˈæm əˌleɪs, -ˌleɪz)

n.
any of several digestive enzymes that break down starches.
[1890–95]

am·y·lase

(ăm′ə-lās′)
Any of various enzymes that break down starches into their component sugars, such as glucose. Amylase is present in fluid secreted by the pancreas, in saliva in some mammals, and in plants.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amylase - any of a group of proteins found in saliva and pancreatic juice and parts of plantsamylase - any of a group of proteins found in saliva and pancreatic juice and parts of plants; help convert starch to sugar
enzyme - any of several complex proteins that are produced by cells and act as catalysts in specific biochemical reactions
ptyalin - an amylase secreted in saliva
Translations
amyláza
amylase
Amylase
amelazo
amülaas
amylaasi
amylase
עמילאז
アミラーゼ
amylase
amylase
amylaza
amylas
амілаза

amylase

[ˈæmɪˌleɪz] namilasi f

amylase

n amilasa
References in periodicals archive ?
Patients who refused to participate in the study, those presenting after 48 hours of onset of pain, patients with other causes of hyperamylasemia and with carcinoma pancreas were excluded from study.
According to the (https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs) press release issued by the FDA, the side effects of taking pretomanid tablets include "damage to the nerves (peripheral neuropathy), acne, anemia, nausea, vomiting, headache, increased liver enzymes (transaminases and gamma-glutamyltransferase), indigestion (dyspepsia), rash, increased pancreatic enzymes (hyperamylasemia), visual impairment, low blood sugar (hypoglycemia), and diarrhea."
The most common adverse reactions observed in patients treated with Pretomanid in combination with bedaquiline and linezolid included damage to the nerves (peripheral neuropathy), acne, anemia, nausea, vomiting, headache, increased liver enzymes (transaminases and gamma-glutamyltransferase), indigestion (dyspepsia), rash, increased pancreatic enzymes (hyperamylasemia), visual impairment, low blood sugar (hypoglycemia), and diarrhea.
The most commonly reported adverse reactions included peripheral neuropathy, acne, anemia, nausea, vomiting, headache, elevated transaminases and gamma-glutamyltransferase, dyspepsia, rash, hyperamylasemia, visual impairment, hypoglycemia, and diarrhea.
Factors affecting pancreatic hyperamylasemia in patients undergoing peroral single-balloon enteroscopy.
Pancreatitis was graded into mild, moderate and severe according to Cotton's criteria10 Secondary outcomes inclu-ded frequency of hyperamylasemia, stent displacement, perforation, hemorrhage and infection.
Results of hematologic testing and plasma biochemical analysis revealed severe leukopenia and heteropenia with toxic heterophils and marked hyperamylasemia and hypoproteinemia, consistent with gastrointestinal dysfunction.
(4) The differential of the P-type (pancreatic) and S-type (salivary) can help in the diagnosis of increased serum levels of amylase known as hyperamylasemia; this would eliminate other causes.
(6-8) Furthermore, a combination of amylase response to secretin and autopsy findings among patients with end-stage renal disease (ESRD) suggests that pancreatitis, found in up to 50% of those cases, is not responsible for all cases of hyperamylasemia in that complex cohort.
N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis.
Hyperamylasemia is a common result of pancreatitis but can also be a reflection of non-pancreatic disease (12).
Sheridan, "Asymptomatic hyperamylasemia and hyperlipasemia in pediatric patients eith toxic epidermal necrolysis," Journal of Burn Care & Research, vol.